- About
- Events
- Resource Center
Archives
Risk Factors For Rapid Disease Progression Of ADPKD
About This Event
Risk Factors For Rapid Disease Progression Of ADPKD
In this presentation rapid disease progression of autosomal dominant polycystic kidney disease (ADPKD) will be defined. The risk factors that assist in determining if a patient is at risk of rapid disease progression will be discussed.
Dallas Nephrology Associates Corporate Office
1505 LBJ Freeway, Suite 700
Dallas, TX 75234 United States + Google Map214.358.2300 View Venue WebsiteFeaturing
Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology, Emory University School of MedicineEmory University School of Medicine*
Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.
Molly Jansen, PhD
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.
*Dr Frederic F Rahbari Oskoui is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Molly Jansen is an employee of OPDC.
Registration
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - Events
